Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus (NASDAQ: EOLS) has announced the issuance of inducement grants to newly hired employees. The company's compensation committee approved the grant of 29,763 restricted stock units (RSUs) to 14 non-executive employees under the Evolus' 2023 Inducement Incentive Plan. The RSUs, which were granted in accordance with Nasdaq Listing Rule 5635(c)(4), will begin vesting on March 7, 2025, with 25% vesting annually over four years. The grants are contingent upon continuous employment through each vesting date and are subject to the terms and conditions of both the incentive plan and the respective RSU agreements.
Evolus (NASDAQ: EOLS) ha annunciato l'emissione di concessioni di indennità per i nuovi assunti. Il comitato per la compensazione dell'azienda ha approvato la concessione di 29.763 unità azionarie vincolate (RSU) a 14 dipendenti non esecutivi nell'ambito del Piano di Incentivazione per Induzione 2023 di Evolus. Le RSU, concesse in conformità con la Regola di Quotazione Nasdaq 5635(c)(4), inizieranno a maturare il 7 marzo 2025, con un 25% di maturazione annuale per quattro anni. Le concessioni sono subordinate a un impiego continuativo fino a ciascuna data di maturazione e sono soggette ai termini e alle condizioni sia del piano di incentivazione che dei rispettivi accordi RSU.
Evolus (NASDAQ: EOLS) ha anunciado la emisión de concesiones de incentivo para los nuevos empleados. El comité de compensación de la empresa aprobó la concesión de 29,763 unidades de acciones restringidas (RSUs) a 14 empleados no ejecutivos bajo el Plan de Incentivos por Inducción 2023 de Evolus. Las RSUs, que se otorgaron de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4), comenzarán a consolidarse el 7 de marzo de 2025, con un 25% de consolidación anual durante cuatro años. Las concesiones están condicionadas a la continuidad del empleo hasta cada fecha de consolidación y están sujetas a los términos y condiciones tanto del plan de incentivos como de los respectivos acuerdos de RSU.
이볼루스 (NASDAQ: EOLS)는 새로 채용된 직원들에게 유인 보상을 발급한다고 발표했습니다. 회사의 보상 위원회는 29,763개의 제한 주식 단위(RSU)를 14명의 비임원 직원에게 이볼루스의 2023 유인 인센티브 계획에 따라 승인했습니다. RSU는 나스닥 상장 규칙 5635(c)(4)에 따라 부여되며, 2025년 3월 7일부터 연간 25%씩 4년에 걸쳐 분할 지급됩니다. 이 보상은 각 분할 지급일까지 지속적인 고용을 조건으로 하며, 인센티브 계획과 해당 RSU 계약의 조건에 따릅니다.
Evolus (NASDAQ: EOLS) a annoncé l'octroi de concessions d'incitation aux nouveaux employés. Le comité de rémunération de l'entreprise a approuvé l'octroi de 29 763 unités d'actions restreintes (RSU) à 14 employés non exécutifs dans le cadre du Plan d'Incentive d'Induction 2023 d'Evolus. Les RSU, qui ont été accordées conformément à la Règle de Cotation Nasdaq 5635(c)(4), commenceront à acquérir des droits le 7 mars 2025, avec un 25% d'acquisition annuel sur quatre ans. Les concessions sont soumises à une continuité d'emploi jusqu'à chaque date d'acquisition et sont soumises aux termes et conditions du plan d'incitation et des accords RSU respectifs.
Evolus (NASDAQ: EOLS) hat die Vergabe von Anreizvergaben an neu eingestellte Mitarbeiter bekannt gegeben. Der Vergütungsausschuss des Unternehmens genehmigte die Vergabe von 29.763 eingeschränkten Aktieneinheiten (RSUs) an 14 nicht-executive Mitarbeiter im Rahmen des Evolus 2023 Anreizplans. Die RSUs, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt wurden, beginnen am 7. März 2025 mit der Vesting-Periode, wobei 25% jährlich über vier Jahre verteilt werden. Die Vergaben sind an eine kontinuierliche Beschäftigung bis zu jedem Vesting-Datum gebunden und unterliegen den Bedingungen des Anreizplans sowie den jeweiligen RSU-Vereinbarungen.
- Employee retention incentive through equity compensation structure
- Continued company expansion with 14 new hires
- Potential future dilution from 29,763 new RSUs
The RSUs vest
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250321283123/en/
Evolus Contacts:
Investors:
Nareg Sagherian
Vice President, Head of Global Investor Relations and Corporate Communications
Tel: 248-202-9267
Email: ir@evolus.com
Media:
Email: media@evolus.com
Source: Evolus
FAQ
How many RSUs did Evolus (EOLS) grant in their latest inducement awards?
What is the vesting schedule for Evolus (EOLS) March 2025 inducement RSUs?
How many new employees received RSU grants from Evolus (EOLS)?
Under which plan were the Evolus (EOLS) inducement grants issued?
